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Glutamine is thought to play an important role in
cancer cells by being deaminated via glutaminolysis
to a-ketoglutarate (aKG) to fuel the tricarboxylic acid
(TCA) cycle. Supporting this notion, aKG supple-
mentation can restore growth/survival of gluta-
mine-deprived cells. However, pancreatic cancers
are often poorly vascularized and limited in gluta-
mine supply, in alignment with recent concerns on
the significance of glutaminolysis in pancreatic can-
cer. Here, we show that aKG-mediated rescue of
glutamine-deprived pancreatic ductal carcinoma
(PDAC) cells requires glutamate ammonia ligase
(GLUL), the enzyme responsible for de novo gluta-
mine synthesis. GLUL-deficient PDAC cells are
capable of the TCA cycle but defective in aKG-
coupled glutamine biosynthesis and subsequent
nitrogen anabolic processes. Importantly, GLUL
expression is elevated in pancreatic cancer patient
samples and inmouse PDACmodels. GLUL ablation
suppresses the development of KrasG12D-driven
murine PDAC. Therefore, GLUL-mediated glutamineCell Re
This is an open access article under the CC BY-Nbiosynthesis couples the TCA cycle with nitrogen
anabolism and plays a critical role in PDAC.INTRODUCTION
Glutamine is the most abundant free amino acid in the human
body (Bergstro¨m et al., 1974). Circulating glutamine enters a
cell via transporters such as SLC1A5. The ‘‘canonical’’ usage
of intracellular glutamine by cancer cells is via glutaminolysis
mediated by glutaminases (GLS) to convert glutamine to gluta-
mate, which can be further deaminated by glutamate dehydro-
genase (GLUD) or glutamate transaminases to a-ketoglutarate
(aKG) that enters the tricarboxylic acid (TCA) cycle for anaplero-
sis (replenishment of metabolic intermediates for energy produc-
tion and biosynthesis) (Altman et al., 2016; Dang, 2012; DeBerar-
dinis and Cheng, 2010; Hensley et al., 2013; Wise and
Thompson, 2010). Oxidation of aKG in the TCA cycle generates
ATP and 4-carbon units. Alternatively, aKG can undergo reduc-
tive carboxylation to generate isocitrate and citrate, and eventu-
ally 2-carbon units for fatty acid synthesis (Mullen et al., 2011).
Cancer cells frequently exhibit an increased dependency on
glutamine (Gao et al., 2009; Wise et al., 2008). This has been
viewed as the result of a shift in cancer cells from glucose oxida-
tion to aerobic glycolysis, known as the ‘‘Warburg effect,’’ whichports 29, 1287–1298, October 29, 2019 ª 2019 The Authors. 1287
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. GLUL Expression Is Increased in Human Cancers
(A) cBioPortal shows increased GLUL amplification across human cancers, including that of breast, lung, and pancreas. Cancers with >6% amplification fre-
quency are shown.
(B) Human Protein Atlas shows increased positive GLUL staining in breast, lung, and pancreatic cancers compared with normal tissues.
(C) Oncomine datasets (https://www.oncomine.org) were analyzed for GLULmRNA expression levels in normal pancreatic tissue and pancreatic cancer. The boxes
represent the interquartile range. Whiskers represent the 10th–90th percentile range. Bars represent the median. The p values were calculated by two-sample t test.
(legend continued on next page)
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effectively starves the TCA cycle of carbon backbones. Inhibition
of this anaplerotic usage of glutamine, in particular by targeting
GLS, has been actively explored for cancer therapy.
However, the explanation for this increased glutamine require-
ment by cancer cells, especially in vivo, has recently become un-
certain. In vivo studies indicate that glutamine addiction is more
complex than merely serving as an anaplerotic carbon source
(Biancur et al., 2017; Davidson et al., 2016). Pancreatic cancers,
possibly due to their highly fibrotic and poorly vascularized na-
ture, have been found to be commonly deprived of nutrients
including glutamine (Kamphorst et al., 2015). GLS inhibition
does not have antitumor effect in vivo in PDAC mouse models
(Biancur et al., 2017). On the other hand, glutamine synthesis,
but not glutaminolysis and oxidation, was found to be increased
in glioblastoma patients and in several mouse tumormodels (Da-
vidson et al., 2016; Maher et al., 2012; Marin-Valencia et al.,
2012; Mashimo et al., 2014). GLUL, aka glutamine synthetase
(GS), the only enzyme identified to be responsible for de novo
glutamine biosynthesis by condensing ammonium and gluta-
mate into glutamine, was found to be elevated in a number of
cancers (Bott et al., 2015; Cox et al., 2016; Tardito et al.,
2015). These studies point to a possible importance of GLUL-
mediated glutamine synthesis and its associated nitrogen
assimilation and transfer to nitrogen-containingmacromolecules
such as nucleotides and hexosamines in cancers, such as
PDAC, where glutamine supply from the circulatory system is
limited. In this study, we sought to determine how GLUL and
the glutamine synthetic reaction contribute to cancer cell meta-
bolism in the context of glutamine addiction, and how they may
impact oncogenesis in vivo, in pancreatic cancers.
RESULTS
GLUL Expression Is Elevated in Human and Mouse
Pancreatic Cancers
We first examined the expression of glutamate metabolizing en-
zymes in human cancers using publicly available databases.
GLUL amplification was prevalent across many human cancers,(D–G) A total of 178 pancreatic adenocarcinoma (PAAD) samples having both RNA
R software was used to plot theGLUL expression among different clinical phenoty
were excluded. (D) GLUL expression positively correlates with pathological stage
TNM staging system. T describes the size of the original (primary) tumor and wheth
are involved.M describes distant metastasis. Note that becausemetastasis data a
and metastasis status. (F) GLUL expression positively correlates with histologica
O-3, International Classification of Disease for Oncology.8140/3: adenocarcinom
8480/3: mucinous adenocarcinoma; 8500/3: infiltrating duct carcinoma, NOS. Not
comparison with other histological types. The bottom and top of the boxes are t
boxes represent the median. The flattened arrows extending out of the box are the
interquartile range (IQR) of the data. 1.5 3 IQR (the interquartile range) was used
(H) A tissue microarray of human pancreatic cancer sections was stained for G
section was assessed blindly and assigned a value ranging from 0–4 according t
represented by each section regraded. Shown in the graph is the intensity score
(I) Representative GLUL staining onWT pancreas (top panel, n = 3) and on tamoxif
harvested at the endpoint (n = 7).
(J) Representative GLUL IHC staining on WT pancreas (top panel) and on panc
panel, n = 4).
(K) Pancreata were isolated from end-stage LSL-KrasG12D/+; Trp53f/f; Pdx1-Cre m
(L) Pancreata were isolated from a WT C57BL/6J mouse and an end-stage KPC
GLUL.with cancers of the breast, lung, and pancreas among those hav-
ing the highest frequency (Figure 1A). This was consistent with
GLUL expression levels detected by immunohistochemistry
(IHC) in these tissues in Human Protein Atlas Database (Uhle´n
et al., 2015; Figure 1B).
Pancreatic tumors are usually highly fibrotic and poorly vascu-
larized. As a result, they are commonly deprived of nutrients
including glutamine (Kamphorst et al., 2015). We thus focused
on the glutamine requirement in pancreatic cancers. GLUL was
upregulatedat themRNA level in several publicly available pancre-
atic cancer studies (Figure 1C). We also extracted data from the
TCGAGDAC Firehose dataset 2016 with a total of 178 pancreatic
adenocarcinoma (PAAD) samples that havebothRNAsequencing
(RNA-seq)andclinicaldata.GLULexpressionpositivelycorrelated
with the pathological stage (Figure 1D), TNM staging system (Fig-
ure 1E), and histological grades (Figure 1F). It is interesting to note
that neuroendocrine carcinoma shows significantly lower GLUL
expression compared to other histological types defined by
ICD-O-3 (Figure 1G). Consistent with the TCGA dataset, using
a tissue microarray (TMA) consisting of 132 human samples
ranging fromnormal tissue to grade 3 pancreatic ductal adenocar-
cinoma (PDAC),weobservedapositivecorrelationbetweenGLUL
expression and humanpancreatic cancer progression (Figure 1H).
Finally,wealsoexaminedGLULexpression in fourcommonlyused
genetically engineered mouse models (GEMMs) for pancreatic
cancer: (1) tamoxifen-inducible Lox-Stop-Lox (LSL)-KrasG12D/+,
Pdx1-CreER (Bardeesy et al., 2006); (2) LSL-KrasG12D/+, Pdx1-
Cre (Hingorani et al., 2005); (3) LSL-KrasG12D/+, Trp53flox/flox (f/f),
Pdx1-Cre (Bardeesy et al., 2006); and (4) LSL-KrasG12D/+,
Trp53R172H/+, Pdx1-Cre (KPC) (Hingorani et al., 2005). In all four
models, GLUL expression was markedly increased in late-stage
PDAC (Figures 1I–1L). These data indicate that elevated GLUL
expression is a common feature in human pancreatic cancers
and in KrasG12D-driven PDAC mouse models.
aKGRescuingGlutamine-DeprivedCells Requires GLUL
We then set out to study the molecular function and physiolog-
ical relevance of GLUL-mediated glutamine synthesis in PDAC.-seq and clinical datawere extracted from TCGAGDACFirehose dataset 2016.
pes. Sub-groups with sample size <5 or clinical information uncertain/unknown
s. (E) GLUL expression positively correlates with tumor development based on
er it has invaded nearby tissue. N describes nearby (regional) lymph nodes that
re not available, we cannot evaluate the association betweenGLUL expression
l grades. (G) GLUL expression based on the histological types defined by ICD-
a, not otherwise specified (NOS); 8246/3: neuroendocrine carcinoma, NOS;
e that neuroendocrine carcinoma shows significantly lower GLUL expression in
he 25th and 75th percentile, respectively, and the bands near the middle of the
minimum andmaximum values that do not exceed a certain distance from the
by default in R. The p values were calculated by two-tailed t test.
LUL by immunohistochemistry (IHC). The relative intensity of staining in each
o the highest level of staining found within the epithelium. The cancer grade is
for each type of tissue in the human tissue microarray.
en-treated LSL-KrasG12D/+; Pdx1-CreER pancreas in invasive PDAC frommice
reata isolated from an end-stage LSL-KrasG12D/+; Pdx1-Cre mouse (bottom
ice and age-matched WT littermates, and stained for GLUL by IHC.
mouse, and stained for GLUL by IHC. Note that normal islets stain positive for
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Figure 2. GLUL Is Required for aKG Rescue of the Cells under Glutamine Limitation
(A) KPC cells were transfected with a plasmid containing Cas9 and three independent sgRNAs targeting mouse GLUL. Single-cell clones were isolated via limited
dilution and screened for expression of GLUL via immunoblotting. Clone 17, which had similar GLUL expression level as the parental cells, was used as a GLUL-
proficient line, and clone 15 was used as a GLUL-deficient line in following studies.
(B) Cells were cultured under glutamine-containing full medium. Cell growth/proliferation was determined by counting cells with a hemocytometer. Shown is the
mean of a representative experiment performed in triplicates plus SD.
(C) Cells were cultured under indicated conditions (+Q: full medium containing glutamine; Q: glutamine-free medium; Q + dmKG: glutamine-free with 6 mM
dmKG) for 72 h. Images were captured using a Keyence BX-Z microscope.
(D) Cells were cultured under indicated conditions for 72 h. Cell confluence was determined via Sartorius IncuCyte.
(legend continued on next page)
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To this end, we generated cancer cell lines derived from both the
KPC and LSL-KrasG12D/+; Pdx1-Cre (KC) mice and usedCRISPR
constructs with three independent single guide RNAs (sgRNAs)
to delete GLUL. Single-cell clones were isolated from the
knockout populations (Figures 2A and S1A). The clones express-
ing GLUL that escaped genetic ablation, which were verified to
have similar GLUL expression levels and growth properties as
the parental cells, were used as GLUL-positive controls (Figures
2A and S1A). In both KC and KPC cells, GLUL ablation did not
lead to a significant alteration of cell proliferation (Figures 2B
and S1B).
The dependence of many cancer cells on glutamine, including
PDAC cells, has been largely attributed to the increased demand
for glutamine as an anaplerotic carbon source for the TCA cycle
via glutaminolysis. This notion is supported by the observation
that the cell permeable form of aKG, dimethyl-aKG (dmKG), res-
cues cells from glutamine deprivation, including PDAC cells (Son
et al., 2013). In our hands, KPC and KC cells were sensitive to
glutamine deprivation (Figures 2C, 2D, S1C, and S1D), which
was partially rescued by dmKG and was further rescued by the
combination of dmKG and nonessential amino acids (NEAA) (a
condition we termed dmKGN) (Figures 2C, 2D, S1C, and S1D)
or by the combination of dmKG and ammonium chloride (Fig-
ure 2E). Strikingly, the dmKG rescue, even in the presence of
NEAA, was completely abolished when GLUL was genetically
silenced (Figures 2C, 2D, S1C, and S1D) or pharmacologically in-
hibited by the GLUL-specific inhibitor methionine sulfoximine
(MSO) (Tardito et al., 2015; Figures 2F and S1E). Reconstitution
of Flag-tagged GLUL in GLUL-deficient KPC and KC cells
rescued cell growth/viability under the dmKGN condition (Figures
2G–2I and S1F–S1H). Similar to the KPC and KC murine PDAC
cells, silencing GLUL in human PDAC cell lines L3.6 with sgRNA
or S2-013 with short hairpin RNA (shRNA), or inhibiting GLUL in
these cells with MSO, also abolished dmKGN rescue (Figures
2J and 2K). Conversely, ectopic expression of GLUL in Mia-
PaCa-2 cells, which displayed low endogenous GLUL expres-
sion, conferred dmKGN rescue upon glutamine-deprivation
(Figure 2L). Taken together, these data indicate that providing
cells with dmKG, the carbon backbone of glutamine, and a nitro-
gen source is sufficient to restore growth in the absence of gluta-
mine. Intriguingly, GLUL is required for the growth restoration,
supporting the hypothesis that the glutamine synthetic pathway,
functioning independently of fueling the TCA cycle, is important
for the rescue of cells by the dmKGN condition.
To further demonstrate that it is glutamine synthesis, but not
the TCA usage of glutamine, that plays a critical role in dmKGN(E) Cells were cultured under indicated conditions for 72 h. Relative cell growth was
to that of the initial cell density (red line). Shown is the mean of a representative
(F) Indicated cell clones were cultured under various conditions. Cells were stain
OD of crystal violet staining and normalized to that of the initial cell density (red
triplicate plus SD. ***p < 0.001.
(G–I) Flag-GLUL was reconstituted in GLUL-deficient KPC cell line (clone 15) (G). C
cell death by propidium iodide (PI) staining (I) were measured by Celigo cell image
SD. ****p < 0.0001.
(J–L) L3.6 human PDAC cell line was lentivirally infected by sgGLUL, representati
line was lentivirally infected by scramble (Scrbl) or shGLUL (J), or treatedwithMSO
(L). Cells were cultured under indicated conditions for 72 h, and relative growth wa
(red line). Shown is the mean of a representative experiment performed in triplicrescue of glutamine deprivation, we used theGLS-specific inhib-
itor BPTES to inhibit glutaminolysis. BPTES did not inhibit the
dmKGN rescue (Figures S2A and S2B). 6-Diazo-5-oxo-L-norleu-
cine (L-DON), a promiscuous inhibitor of a wide spectrum of
transaminases hencemany glutamine usage pathways including
nucleotide and hexosamine biosynthesis, inhibited dmKGN
rescue (Figures S2A and S2B).
aKG is an important metabolite that is at the converging point
of the TCA cycle and glutaminolysis. In addition, aKG is coupled
with several nitrogen scavenging reactions that might be occur-
ring upstream of glutamine synthesis, including those mediated
by glutamate-oxaloacetate transaminase (GOT), glutamate-
pyruvate transaminase (GPT), phosphoserine transaminase
(PSAT), and glutamate dehydrogenase (GLUD), to convert aKG
to glutamate as the substrate for GLUL. To test which glutamate
generation mechanism is critical for dmKGN rescue, cells were
cultured with dmKGN and treated with various inhibitors of gluta-
mate producing enzymes: the GOT inhibitor aminooxyacetic
acid (AOA), the GPT inhibitors cycloserine and b-chloro-
L-alanine, and the GLUD inhibitor epigallocatechin gallate
(EGCG). AOA, cycloserine, and b-chloro-L-alanine each caused
a modest reduction in growth while EGCG had no observable
effect (Figures S2C and S2D). These data suggest that under
glutamine-starvation condition, cells may be capable of scav-
enging nitrogen from multiple sources such as alanine and
aspartate to transaminate aKG to produce glutamate as a sub-
strate for glutamine synthesis.
aKG Is Coupled with Nitrogen Assimilation and
Anabolism in a GLUL-Dependent Manner
aKG is a pleiotropic molecule that serves as a metabolite and as
a co-factor for numerous enzymes. As a metabolite, aKG can be
converted to succinate by the oxoglutarate dehydrogenase
(OGDH) complex, to citrate via reductive carboxylation by isoci-
trate dehydrogenase 2 (IDH2), and to glutamate via transamina-
tion or GLUD-mediated amination of its alpha carbon (Figure 3A).
As dmKG could rescue GLUL-proficient but not GLUL-deficient
cells from glutamine deprivation, we determined whether aKG is
being used to produce glutamine in GLUL-proficient cells, and
whether the TCA cycle usage of aKG are affected by GLUL. To
address this, we chemically modified the isotope tracer of
13C5-aKG to the cell-permeable dimethyl form (Figures 3B and
S3A), which was not commercially available, and determined
whether 13C5-dmKG would contribute to the three metabolic
fates: to succinate via oxidation, to citrate/isocitrate via reduc-
tive carboxylation, and to glutamate then glutamine (Figure 3C).determined by the optical density (OD) of crystal violet staining and normalized
experiment performed in triplicate plus SD. ***p < 0.001.
ed by crystal violet and photographed. Relative growth was determined by the
dashed line). Shown is the mean of a representative experiment performed in
ells were cultured under indicated conditions for 72 h. Relative growth (H) and
r. Shown is the mean of a representative experiment performed in triplicate plus
ve GLUL-proficient and -deficient clones are shown. S2-103 human PDAC cell
(K). MiaPaCa-2 humanPDAC cell line stably expressingGLULwas established
s determined by crystal violet staining normalized to that of the initial cell density
ate plus SD. ***p < 0.001.
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Figure 3. GLUL Is Essential for Cataplerotic Nitrogen Transfer but Not Anaplerotic Usage of aKG
(A) Schematic of proximal labeling patterns from 13C-aKG indicating the metabolic fates for aKG catalyzed by respective enzymes.
(B) Chemical reaction was performed to modify 13C5-aKG to cell permeable
13C5-dmKG. *C =
13C.
(C) GLUL-proficient and -deficient KPC cells were cultured in glutamine-free medium supplemented with 1.5 mM 13C-dmKG for 24 h. Polar metabolites were
extracted and subjected to liquid chromatography-mass spectrometry (LC-MS). Total labeling of indicated metabolite is shown. Shown is the mean of a
representative experiment performed in triplicate plus SD. ***p < 0.001.
(D) Basal OCR and ATP production of GLUL-proficient and -deficient cells after 1 h treatment in DMEM (+Q), DMEM no glutamine (Q) or DMEM no glutamine
supplemented with a-ketoglutarate (Q+dmKG).
(E) Schematic of labeling patterns from 15N-NH4Cl.
(F) GLUL-proficient and -deficient KPC cells were cultured in glutamine-free medium supplemented with 6 mM dmKG and 1 mM 15N-NH4Cl for 24 h. Polar
metabolites were extracted and subjected to LC-MS. Total labeling of indicated metabolite is shown as means of a representative experiment performed in
triplicate plus SD. **p < 0.01; ***p < 0.001.In both GLUL-proficient and -deficient cells, culturing with
13C5-dmKG in glutamine-free medium resulted in similar
13C
labeling of aKG, glutamate, succinate, fumarate, malate, and
citrate (Figure 3C), which was accompanied by similar oxygen
consumption and ATP production in both GLUL-proficient and
-deficient cells cultured in glutamine-freemedium supplemented
with dmKG (Figure 3D). Similarly, labeling of aspartate, which1292 Cell Reports 29, 1287–1298, October 29, 2019contributes carbons to nucleotide synthesis, was similar be-
tween GLUL-proficient and -deficient cells (Figure 3C). These re-
sults indicate that GLUL-deficient cells are fully competent for
the TCA cycle. Importantly, in addition to the anaplerotic TCA
usage, aKG was being converted to glutamate in both GLUL-
proficient and -deficient cells, however, the conversion to gluta-
mine was only observed in GLUL-proficient cells (Figure 3C).
Figure 4. Ablation of GLUL Suppresses PDAC Development in KPC Mice
(A) GLULf/f mice was bred to LSL-KrasG12D/+;Trp53f/f;Pdx1-Cremice. H&E and GLUL IHC staining were performed on 3-week-old GLUL+/+ and GLULf/f mice. The
middle panels are zoom-in photomicrographs of the boxed areas in the left panels.
(B) The number and size of ductal carcinoma foci (n = 3 for each genotype) were scored blindly and plotted. ***p < 0.001.
(C) Kaplan-Meier plot comparing GLUL+/+, GLULf/+, and GLULf/f mice in the LSL-KrasG12D/+; Trp53f/f; Pdx1-Cre background.
(D and E) Representative PCNA IHC staining (D) and O-GlcNAc staining (E) of the pancreas on 3-week-old GLUL WT and GLUL knockout (KO) mice. The right
panels are zoom-in photomicrographs of the boxed areas showing more PCNA-positive or O-GlcNAc-positive cells in the WT pancreas. ImageJ was used and
images were subjected to color deconvolution to remove hematoxylin counterstaining while PCNA or O-GlcNAc staining remained for further quantification.
Intensity of PCNA or O-GlcNAc staining in randomly selected areas were quantified. The p value was calculated by two-tailed-t test.
(legend continued on next page)
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Consistently, unlike the GLUL-deficient cells that could not be
rescued from glutamine deprivation by dmKGN, silencing an
OGDH component dihydrolipoamide S-succinyltransferase
(DLST), which is essential for the aKG to succinate conversion,
and IDH2, which is responsible for reductive carboxylation of
aKG to citrate, did not affect the ability of dmKGN to rescue cells
from glutamine deprivation (Figure S3B). Similarly, TCA cycle
and reductive carboxylation were unchanged in the human
PDAC cell lines L3.6 with sgGLUL silencing, BxPC3 with MSO
treatment, and MiaPaCa-2 with GLUL overexpression (Figures
S3C and S4). The majority of labeled glutamine was m+5 in all
tested GLUL-proficient cell lines (Figure S4), indicating a direct
conversion of aKG to glutamate then glutamine. These data indi-
cate that while aKG can be used for both TCA cycle anaplerosis
and as a direct substrate for glutamate then glutamine synthesis,
the latter, which is mediated by GLUL, plays an essential role in
rescuing cell proliferation in glutamine-deprived conditions.
GLUL assimilates ammonia by adding the amide group to the
terminal carbon in glutamate, which can be traced by culturing
cells in the presence of 15N-NH4Cl. This terminal amide can be
further traced to determine the contribution of GLUL-mediated
ammonia assimilation and nitrogen transfer into other nitrogen-
containing molecules (Figure 3E). In the presence of excess un-
labeled glutamine, the fraction of 15N-labeled glutamine was
barely detectable in both KPC and KC PDAC cells (Figures
S5A and S5B), indicating that they do not engage in glutamine
synthesis when glutamine can be acquired from the environ-
ment. However, upon glutamine deprivation, GLUL-proficient
cells were able to utilize 15N-NH4Cl to synthesize glutamine de
novo, and this fraction was significantly increased upon addition
of dmKG (Figures 3F, S5A, and S5B). These data suggest that
upon glutamine deprivation, carbon sources for de novo gluta-
mine synthesis might be required to generate glutamine for
various metabolic processes. In this regard, we examined me-
tabolites that can be synthesized using the amide nitrogen
from glutamine including nucleotides and hexosamine. Indeed,
significant increases in fractional labeling in nucleotides and
UDP-GlcNAc were observed upon the addition of dmKG in the
GLUL-proficient cells (Figure 3F). Glutamine-specific isotopic la-
beling, such as m+3 labeled AMP/ADP/ATP, was observed only
in the GLUL-proficient cells, but not in GLUL-deficient cells (Fig-
ures S5A and S5B). UDP-glucose isotopologues (m+1 and m+2)
indicate that the uridine component was labeled at both nitro-
gens, which was consistent with the UTP result (Figures S5A
and S5B). UDP-GlcNAc showed a specific labeling of m+3 in
the GLUL-proficient but not-deficient cells, indicating that the
m+3 fraction is derived from GLUL-mediated synthesis of
glutamine (Figures S5A and S5B). In contrast, the fraction of(F and G) GLUL WT or KO LSL-KrasG12D/+;Trp53f/f;Pdx1-Cre mice had catheters
infused. Animals were sacrificed and organs were rapidly collected for metabolom
kidney. (G) Decreased m+1 Gln/m+0 Glu and m+2 Gln/m+1 Glu ratios indicate d
(H) Both labeled and total UDP-GlcNAc are trending to be decreased in KO panc
(I) Ex vivo 13C5-dmKG labeling were performed using WT and KO pancreata. The t
glutamine free DMEMsupplementedwith 10%dialyzed FBS and 1.5mM 13C5-dm
and subjected to LC-MS. Note the decreased ratio of m+5 labeled glutamine to
aKG in the KO or MSO-treat WT tissues, indicating defective conversion of Glu to
mean ± SD.
1294 Cell Reports 29, 1287–1298, October 29, 201915N-labeled aspartate, which is produced by the transamination
of the alpha amino group of glutamate, did not vary between
GLUL-proficient and -deficient cells (Figure 3F). These results
indicate that GLUL-mediated de novo synthesis of glutamine
plays an essential role in transferring the terminal amide nitrogen
to nucleotides and hexosamines, which correlates with the
GLUL-dependent survival/growth in glutamine-deprived cells.
We had been unable to rescue cell growth of glutamine-deprived
GLUL-deficient cells using nucleotides and UDP-GlcNAc, likely
owing to the pleiotropic effects of glutamine. Nonetheless,
consistence with the importance of O-glycosylation, the
O-GlcNAc transferase (OGT) inhibitor OSMI-1 inhibited cell
growth and the dmKGN-rescue in GLUL-proficient cells (Figures
S5C and S5D). Taken together, these findings demonstrate the
importance of glutamine anabolism in promoting de novo nucle-
otide and hexosamine biosynthesis, which conceivably plays a
critical role in cell growth under glutamine starvation.
Genetic Ablation of GLUL Suppresses PDAC
Our cell culture study indicates that GLUL expression is critical
for cell growth/proliferation under glutamine-limited conditions.
The pancreatic tumor environment is low in glutamine (Kam-
phorst et al., 2015), and GLUL is highly expressed in PDAC (Fig-
ure 1). Hence, we next sought to determine the in vivo role of
GLUL using the PDAC mouse models. Because we observed
increased GLUL expression in all four genetically engineered
PDAC mouse models (Figures 1E–1H), we examined the LSL-
KrasG12D/+;Trp53f/f;Pdx1-Cre model bred to mice with floxed
GLUL alleles (He et al., 2010). GLUL ablation significantly de-
layed tumor development: 3-week-old GLUL+/+ animals showed
substantial PDAC lesions but no detectable lesionswere found in
the GLULf/f animals (Figures 4A and 4B). GLUL+/+ mice devel-
oped several foci of invasive PDAC (Figure 4A, top left panel),
which showed infiltrative and haphazard glands, high nuclear-
cytoplasm ratio, single cells, and a desmoplastic reaction (Fig-
ure 4A, top middle panel). However, the GLULf/f mice showed
mostly normal pancreatic parenchyma, no invasive carcinoma,
and only occasional foci of high-grade pancreatic intraepithelial
neoplasia (PanIN) (Figure 4A, bottom left panel), which exhibited
loss of nuclear polarity, marked nuclear pleomorphism, promi-
nent nucleoli, cribriform architecture, and frequent mitosis (Fig-
ure 4A, bottommiddle panel), but no invasive foci. IHC confirmed
the presence of GLUL protein in the GLUL+/+ but not in GLULf/f
ductal epithelia, with a low expression apparent in stromal cells
(Figure 4A, right panels). GLULf/f mice showed significantly
increased median survival (GLUL+/+: 33 d, GLULf/f: 67 d, Fig-
ure 4C). Consistent with the cell culture results showing defec-
tive nucleotide and hexosamine synthesis (Figures 3 and S5),implanted surgically into jugular veins. Stable isotope tracer 15N-NH4Cl was
ics. (F) Total counts of 15N1-glutamine (M+0.997) is shown from pancreas and
efective GLUL function in the KO pancreata.
reata, indicating defective hexsosamine synthesis.
umor-laden pancreas was roughly divided into multiple pieces then cultured in
KG in the presence or absence ofMSO (100 mM) for 1 h. Tissueswere harvested
m+5 labeled glutamate and a reciprocal increased ratio of m+5 glutamate to
Gln. Each dot represents a piece of tissue (n = 3 mice in each group), bar shows
GLUL knockout (KO) pancreata had markedly lower proliferation
index as indicated by PCNA staining (Figure 4D) and O-glycosyl-
ation (Figure 4E). Interestingly, in the KO mice that still suc-
cumbed to PDAC development and death, the stromal areas
(positive for Sirius Red staining) showed high GLUL expression
(Figure S6), consistent with the observations in other cancer
types that the stroma may supply tumor cells’ glutamine needs
(Yan et al., 2018; Yang et al., 2016).
To determine whether active glutamine synthesis occurs
in PDAC in vivo, we performed jugular vein infusion of
15N-NH4Cl in GLUL wild-type (WT) and KO mice. We observed
a significant decrease in the amount of m+0.997 (15N1)-
labeled glutamine in the KO pancreas, but not in the kidney
of paired animals (Figure 4F). The ratio of m+1 glutamine
versus m+0 glutamate and that of m+2 glutamine versus
m+1 glutamate, both indicative of GLUL-mediated conversion
of glutamate to glutamine, were lower in the KO mice (Fig-
ure 4G). Consistent with the result observed in cultured cells
(Figure 3F) and in vivo (Figure 4E), GLUL-dependent nitrogen
transfer from 15N-NH4Cl to UDP-GlcNAc was also reduced
in GLUL-KO PDAC (Figure 4H). To unequivocally show that
the conversion of aKG to glutamate then glutamine occurs
in PDAC, we attempted to perform in vivo tracing with 13C5-
dmKG, yet found that the in vivo labeling of 13C5-dmKG
via jugular vein infusion was extremely inefficient. Hence,
instead, we performed ex vivo 13C5-dmKG tracing using
tissue sections of tumor-laden pancreata isolated from
GLUL WT and KO mice. Indeed, a lower ratio of m+5 gluta-
mine versus m+5 glutamate and a reciprocal higher ratio of
m+5 glutamate versus m+5 aKG were observed in the KO
pancreata and in MSO-treated WT pancreata than in un-
treated WT pancreata (Figure 4I), indicating a blockade of
glutamate to glutamine conversion when GLUL was inhibited
genetically or pharmacologically.
Cell Autonomous Inhibition of GLUL Leads to Decreased
Tumor Growth
Because the above mouse PDAC model showed increased
GLUL expression in the stroma, we went on to further address
the cell autonomous effect of GLUL ablation in PDAC. To this
end, we silenced GLUL in KPC organoids in culture and then
orthotopically implanted them into the pancreas of immunocom-
promised nude mice. We also used a syngeneic orthotopic
model in which GLUL was silenced in the KC PDAC cells in
culture and then orthotopically injected into the pancreas of
immunocompetent C57BL6/J mice. While silencing GLUL in
KPC organoids and in the KC cell culture did not alter their
growth in vitro in glutamine replete conditions (Figures 5A and
S1B), tumor development was significantly delayed in both
models with GLUL downregulation (Figures 5B–5E), supporting
an essential role of GLUL in PDAC cell growth in a cell autono-
mous fashion in vivo.
DISCUSSION
Glutamine is a multifunctional amino acid. In addition to its
familiar role as a constituent of proteins, glutamine is an ana-
plerotic substrate for the TCA cycle, contributing its carbonbackbone particularly in conditions of carbon diversion to
glycolytic pathways. However, glutamine is also the obligatory
nitrogen donor for the biosynthesis of purines, pyrimidines,
NAD, asparagine, and hexosamines via its terminal amide
group. Glutamine also drives the uptake of essential amino
acids, activates mTOR, helps recycle excessive ammonia
and glutamate, and regulates redox homeostasis (Altman
et al., 2016; Cluntun et al., 2017; De Vitto et al., 2016). These
high and diverse demands for glutamine cannot be met from
steady-state endogenous production, which occurs mainly
in the muscle, or solely from regular organismal dietary
protein digestion, as is the case for many other amino acids.
Addditionally, glutamine demand cannot be satisfied by
macropinocytosis and/or autophagic digestion at the cellular
level. As a result, many tissues upregulate GLUL to increase
glutamine synthesis, particularly at times of enhanced meta-
bolic need, increased growth or stress, such as pathogen
infection. It is conceivable that this situation is exacerbated
in tumor cells because of their high proliferation rate and often
poor vascularization, therefore limiting access to circulating
glutamine.
In this study, we report that GLUL is essential for cancer cell
proliferation under glutamine limitation allowing cells to utilize
other components such as aKG and ammonium to synthesize
glutamine to support proliferation. The use of aKG in a non-
TCA cycle manner has been appreciated in the context of it
functioning as a co-factor for dioxygenases to regulate the
epigenetic state (Carey et al., 2015) or to respond to DNA dam-
age (Tran et al., 2017). Here, we show, by tracing 13C-dmKG,
that aKG can be used to synthesize glutamine under the condi-
tion of metabolic stress, in addition to fueling the TCA cycle.
These data indicate that glutamine addiction is more complex
than merely serving as an anaplerotic carbon source for energy
and biosynthetic demands of a proliferating cell, especially in
the tumor microenvironment where vastly different metabolic
co-dependencies occur compared with in vitro conditions
(Biancur et al., 2017; Davidson et al., 2016). Our results are
consistent with the findings that tumor cells, including PDAC
cells, often have increased dependence on aspartate and
alanine as well as their transaminases GOT and GPT. GOT
and GPT can convert aspartate and alanine to oxaloacetate
and pyruvate to provide carbon source for the TCA cycle and
nucleotide synthesis, as well as to facilitate mitochondrial elec-
tron transport and maintaining redox homeostasis (Son et al.,
2013; Sousa et al., 2016; Tajan et al., 2018). These reactions
are coupled with the conversion of aKG to glutamate. aKG is
also used by GLUD to assimilate ammonia as an intracellular
metabolic waste product to generate glutamate (Spinelli et al.,
2017). Several sources including glucose, lactate, and
branched chain amino acids can supply TCA cycle carbons to
replenish aKG (Hui et al., 2017; Jones et al., 2018; Neinast
et al., 2019). Therefore, in addition to its critical roles as a TCA
cycle metabolite and an enzymatic cofactor, aKG can serve
as a central nitrogen receptor via the transamination and
ammonia assimilation reactions to generate glutamate, one of
whose metabolic fates is to be converted to glutamine by
GLUL. It remains to be determined whether specific transami-
nases play a more predominant role in aKG-glutamateCell Reports 29, 1287–1298, October 29, 2019 1295
Figure 5. Inhibition of GLUL Decreased Tumor Growth
(A) In vitro proliferation of KPC tumor cell organoids, in which GLUL inactivation through CRISPR-Cas9 gene editing was determined by immunoblotting, was
measured by CellTiter-Glo. Relative growth was determined by normalizing the reading of cells plated at time 0. Shown is the mean plus SEM of 5 replicates.
(B) Bright-field/GFP images and tumor weights of tumors from nude mice orthotopically transplanted with the KPC organoids. Each dot represents one mouse.
(C) KC cells (5 million) stably expressing luciferase and lentiviral sgGLUL (GLUL-proficient, clone 3 or GLUL-deficient, clone 4) were implanted in the head of the
pancreas of C57BL/6 mice. Tumor growth was monitored by IVIS imaging of the luciferase signal on weeks 1 and 2 after implantation. Representative images of
2 mice in each group are shown.
(D) Quantification of luciferase signals from each mouse. Each dot represents one mouse. The bars indicate the median. **p < 0.01.
(E) Kaplan-Meier survival curves for the mice implanted with the indicated cell lines. Median survival: GLUL-proficient (clone 3), 29 days (n = 8); GLUL-deficient
(clone 4), 56 days (n = 7). p = 0.002 (log-rank test).conversion in the context of glutamine biosynthesis. Nonethe-
less, our study indicates that GLUL-mediated glutamine syn-
thesis on one hand facilitates ammonium assimilation and
transamination reactions that are coupled with the TCA cycle,
and on the other hand plays an essential role in glutamine-
dependent nitrogen anabolism. While we cannot completely
rule out the contribution of GLUL’s other enzymatic activities in-
dependent of glutamine synthesis (Eelen et al., 2018), our data
demonstrate that GLUL-mediated glutamine anabolism plays a
critical role in the biosynthesis of nucleotides and hexosamines
and subsequent cell growth and proliferation.
It is important to note that GLUL expression is consistently
elevated in human pancreatic cancer and in several PDAC
mousemodels (Figure 1). While this increasedGLUL expression
may be an adaptive response to the scarcity of nutrients espe-
cially glutamine itself, the underlying mechanisms remain to be
determined. Several possibilities exist including gene amplifica-
tion, transcriptional upregulation, and increased protein stabil-
ity. An interesting possibility is that GLUL upregulation occurs
through increased c-Myc activity and epigenetic regulation
that are largely associated with PDAC development and aKG
metabolism (Bott et al., 2015). Importantly, unlike GLS, whose
ablation does not have an overt effect on PDAC development1296 Cell Reports 29, 1287–1298, October 29, 2019in vivo (Biancur et al., 2017), GLUL germline ablation leads to
a significant delay in disease progression (Figures 4A–4C),
which is accompanied by decreased O-glycosylation and cell
proliferation (Figures 4D and 4E). Cancer cell autonomous inhi-
bition of GLUL by CRISPR/Cas9 significantly decreased tumor
growth (Figure 5), at least in the murine models. These data
suggest that targeting the glutamine-nitrogen assimilation axis
in tumor cells may be an ample approach to therapy. The
incomplete inhibition of tumorigenesis in our studies is likely a
result of the induction of GLUL expression in the stroma, thus
increasing local supply of glutamine. Therefore, it may be
important to concurrently target both tumor and stromal cells
when considering developing GLUL inhibition as a therapeutic
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Antibodies
GLUL, rabbit polyclonal Sigma Cat # G2781; RRID:AB_259853
GLUL, rabbit polyclonal Abcam Cat #Ab73593; RRID:AB_2247588
GLUL, mouse monoclonal BD Cat #610517
b-tubulin, mouse monoclonal Sigma Cat #T9026; RRID:AB_477593
Hsp90, rabbit polyclonal Millipore Cat #07-2174; RRID:AB_10807022
GAPDH, mouse monoclonal Cell Signaling Cat #97166; RRID:AB_2756824
DLST, rabbit polyclonal Abnova Cat #H00001743-D01; RRID:AB_10720339
PCNA, rabbit monoclonal Cell Signaling Cat #13110; RRID:AB_2636979
O-GlcNAc, mouse monoclonal Cell Signaling Cat #9875; RRID:AB_10950973
Bacterial and Virus Strains
pLKO.1 Addgene 8453
pLenti-sgRNA-EFS-Neo-IRES-GFP Roe et al., 2017 N/A
pLenti-Cas9-Puro Addgene 108100
Biological Samples
Pancreatic cancer tissue microarray (de-identified) Laboratory of Howard Crawford,
University of Michigan
N/A
Chemicals, Peptides, and Recombinant Proteins
L-methionine sulfoximine (MSO) Sigma M5379
6-diazo-5-oxo-L-norleucine (L-DON) Sigma D2141
BPTES Sigma SML0601
Cycloserine Sigma C1159
Direct Red 80 Sigma 365548
Picric acid Sigma 197378
OSMI-1 Sigma SML1621
Aminooxyacetic acid (AOA) Sigma C13408
Epigallocatechin gallate (EGCG) Hara Office Inc N/A
m-chloro-L-alanine Santa Cruz Biotechnology sc-291972
15N-NH4Cl Cambridge Isotope Laboratories NLM-467-PK
13C5-aKG Cambridge Isotope Laboratories CLM-2411-PK
13C5-dmKG This paper N/A
Experimental Models: Cell Lines
FC1245 (KPC) pancreatic cancer cell line Roy et al., 2015 N/A
UN-KC-6141 (KC) pancreatic cancer cell line Torres et al., 2013 N/A
S2-013 Thermo-Fisher CVCL-B280
MIA PaCa-2 ATCC CRL-1420
L3.6 Bruns et al., 1999 N/A
Experimental Models: Organisms/Strains
Mouse LSL-KrasG12D, mixed 129sv/C57B6 Jackson et al., 2001 N/A
Mouse LSL-KrasG12D;p53f/f, mixed 129sv/C57B6 Jackson et al., 2001 N/A
Mouse Pdx1-Cre, mixed FVB/C57B6 Jackson Laboratory 014647
Mouse GLULf/f (mixed 129/Ola and C57BL/6) He et al., 2010 N/A
Mouse C57Bl6.J Jackson Laboratory 000664
Mouse Crl:NU-Foxn1nu Charles River 088
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REAGENT or RESOURCE SOURCE IDENTIFIER
Oligonucleotides
Mouse shDLST#1: TGTCTCATAGCCTCGAATATC This paper N/A
Mouse shDLST#2: CGAAAGAATGAACTTGCCATT This paper N/A
Control sgRNA: sgRosa26: GAAGATGGGCGGGAGTCTTC This paper N/A
Mouse sgGLUL#1: TGGGATCGTAGGCGCGAATG This paper N/A
Mouse sgGLUL#2 CATTCGCGCCTACGATCCCA This paper N/A
Mouse GLUL sgRNA mixture Santa Cruz sc-420579
Human sgGLUL: GCGCTGCAAGACCCGGACCC This paper N/A
Mouse GLUL shRNA #1 Sigma NM_008131, #1: TRCN0000309816
Mouse GLUL shRNA #2 Sigma NM_008131, #1: TRCN0000309745
Recombinant DNA
LPC-FLAG-GLUL (human) This paper N/A
Software and Algorithms
MAVEN Melamud et al., 2010 N/A
AccuCor Su et al., 2017 N/ALEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Wei-Xing
Zong (zongwx@rutgers.edu).
Materials Availability Statement
13C5-dmKG generated in this study will be made available on request but we may require a payment and/or a completed Materials
Transfer Agreement if there is potential for commercial application. Requests of the GLULf/f mouse line will be directed to its original
source. All the rest reagents generated in the study will be made available upon requests. All materials are described in the KEY
RESOURCES TABLE. Further information and requests for resources and reagents should be directed to and will be fulfilled by
the Lead Contact, Wei-Xing Zong (zongwx@rutgers.edu)
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animal strain, age, sex, and number
For the spontaneous PDAC models, we used LoxP-Stop-LoxP (LSL)-KrasG12D (Jackson et al., 2001) (mixed 129sv/C57B6);
LSL-KrasG12D;p53f/f (Jackson et al., 2001); Pdx1-Cre (mixed FVB/C57B6); GLULf/f (mixed 129/Ola and C57BL/6) (He et al., 2010).
For the orthotopic tumor models, C57BL/6J mice were used. For the in vivo organoid models, Nu/Nu mice were used. Mouse
experiments were performed at the age of 6-8 weeks unless specified otherwise.
Spontaneous tumor models
Both male and female mice were used. Backcross were carried out to reach a mixed background, and gender and age-matched
littermate animals were used for experiments. Crossing were carried out to obtain the proper controls and to meet statistical
requirement, and to minimize the number of animals needed to obtain the experimental conditions. To develop spontaneous
pancreatic GLUL/, KrasG12D/+, p53/ mouse model, we crossed LSL-KrasG12D/+ mice with p53f/f mice to generate LSL-
KrasG12D/+;p53f/f mice. Thesemice were further crossed with GLULf/f mouse to generate GLULf/+;LSL-KrasG12D/+; p53f/f mice. Simul-
taneously, we crossed GSf/f mice with Pdx1-Cre to generate Pdx1-Cre;GLULf/+ mice. The resultant progeny triple transgenic animals
(GLULf/+;LSL-KrasG12D/+;p53f/f) were crossed with double transgenic Pdx1-Cre (or Pdx1-CreER);GLULf/+ mice to generate KPG
(GLULf/f;LSL-KrasG12D/+;p53f/f;Pdx1-Cre mice and their contemporary littermate controls.
Cell culture
The FC1245 cells (KrasG12D/+;Trp53R172H/+;Pdx1-Cremouse pancreatic cancer cell line) (Roy et al., 2015) were named KPC cells. The
UN-KC-6141 cell line (KrasG12D mouse pancreatic cancer cell line, named KC) was a kind gift from Dr. Surinder Batra (University
of Nebraska Medical Center). KC cells were infected with a lentiviral vector encoding firefly luciferase under CMV promoter control
(Cellomics Technology). S2-013, MiaPaCa-2, and L3.6 human PDAC cell lines were obtained from ATCC. KPC, KC, S2-013, and
MiaPaCa-2 cells were cultured in DMEM supplemented with 10% bovine serum (Fetal Clone III, HyClone), 100 units/ml penicilline2 Cell Reports 29, 1287–1298.e1–e6, October 29, 2019
and 100 mg/ml streptomycin. L3.6 cells were cultured in RPMI supplemented with 10% bovine serum (Fetal Clone III, HyClone),
100 units/ml penicillin and 100 mg/ml streptomycin.
For conditioned media with glutamine deprivation, glutamine-free DMEM (ThermoFisher 11960044) was used. It was supple-
mented with dialyzed FBS (Gemini 100-108) and the following substances individually or in combination: L-glutamine (ThermoFisher
25030081) at 2 mM, dimethyl-2-oxoglutarate (dmKG, Sigma 349631) at 6 mM, non-essential amino acid mixture (ThermoFisher
11140050) at 0.1 mM of each amino acid, NH4Cl (Sigma 243134) at 1 mM, aspartate (Sigma A9256) at 1 mM, alanine (Sigma
A7469) at 1 mM.
METHOD DETAILS
Chemicals
L-methionine sulfoximine (MSO; Sigma M5379) at 100 mM for cultured cells or tissues and 10 mg/kg for mouse experiments,
L-asparaginase (ASNase) at 0.5 IU/ml for cultured cells and 3 IU/g for mouse experiments, 6-Diazo-5-oxo-L-norleucine (L-DON;
Sigma D2141) at 25 mM, BPTES (Sigma SML0601) at 10 mM, aminooxyacetic acid (AOA, Sigma C13408) at 500 mM, epigallocatechin
gallate (EGCG, kindly provided by Dr. Yukihiko Hara at Tea Solutions, Hara Office Inc) at 50 mM, m-chloro-L-alanine (Santa Cruz
Biotechnology sc-291972) at 250 mM, cycloserine (Sigma C1159) at 250 mM, Direct Red 80 (Sigma 365548), Picric acid (Sigma




Antibodies were purchased from the indicated sources: GLUL (SigmaG2781, 1:1,000 for IB, 1:800 for IHC; Abcam, ab73593, 1:1,000
for IB; BD 610517, 1:1,000 for IHC), b-tubulin (Sigma T9026, 1:10,000 for IB), Hsp90 (Millipore 07-2174, 1:2,000 for IB), GAPDH (Cell
Signaling #97166, 1:1,000 for IB), DLST (Abnova H00001743-D011:1,000 for IB), IDH2 (ProteinTech 15932-1-AP, 1:1,000 for IB),
PCNA (Cell Signaling 13110, 1:8,000 for IHC), O-GlcNAc (CTD110.6, Cell Signaling #9875, 1:100 for IHC), GOT1 (Proteintech
14886-1-AP, 1:1,000 for IB), PSAT1 (Proteintech 10501-1-AP, 1:1,000 for IB), GLUD1 (Proteintech 14299-1-AP, 1:1,000 for IB).
Plasmids
Expression: mouse GLUL expression cDNAwas cloned into pLPC retroviral vector. Short-hairpin RNA (shRNA): pLKO-based shRNA
plasmids were purchased from Sigma-Aldrich
Mouse GLUL shRNA (NM_008131, #1: TRCN0000309816; #2: TRCN0000309745). Human IDH2 shRNA (SHCLNG-NM_002168,
#1: TRCN0000229434; #2: TRCN0000229778). The following sequences against DLSTwere cloned into pLKO.1 plasmid: shDLST#1:
TGTCTCATAGCCTCGAATATC; shDLST#2: CGAAAGAATGAACTTGCCATT. CRISPR/Cas9 short guide RNA (sgRNA): for the orga-
noid study, sgRNAs were cloned into the LRNG vector (pLenti-sgRNA-EFS-Neo-IRES-GFP) (Roe et al., 2017). Control sgRNA:
sgRosa26 GAAGATGGGCGGGAGTCTTC; for mouse GLUL silencing, sgGLUL#1: TGGGATCGTAGGCGCGAATG; sgGLUL#2
CATTCGCGCCTACGATCCCA. pLenti-Cas9-Puro (Addgene #108100) was used for the expression of spCas9. For human cell cul-
ture, sgRNA of human GLUL was cloned into pLentiCRISPRv2 (Addgene #52961). sgGLUL: GCGCTGCAAGACCCGGACCC. For
mouse cell culture and orthotopic studies, a pool of three plasmids each containing a 20 nt guide RNA sequence specific to mouse
GLUL was purchased from Santa Cruz Biotechnologies (sc-420579).
Immunoblotting
Cell lysates were prepared in 1% sodium deoxycholate, 0.1% SDS, 1% Triton X-100, 0.01 M Tris pH8.0, 140 mM NaCl. Protein ly-
sates were separated in SDS-PAGE. All primary antibodies were incubated overnight at 4C. Alexafluor-conjugated goat anti-rabbit
(IRDye800, Rockland) or goat anti-mouse (Alexafluor-680, Life Technologies) antibodies were used as secondary antibodies
(1:10,000). Immunoblots were developed using an Odyssey Imager (LI-COR).
For immunoblotting of organoids, organoids were lysed with 20 mM HEPES; 300 mM NaCl; 1% Triton X-100; 5 mM EDTA; 10%
Glycerol supplemented with protease inhibitors (Mini, Roche). Protein lysates were separated in 4%–12% Bis-Tris NuPage gels (Life
Technologies). Immunoblots were probed with anti-Hsp90 (Millipore, 07-2174) and anti-GLUL (Abcam, ab73593) antibodies.
Histology and immunohistochemistry
Paraffin-embedded pancreas sections were stained with hematoxylin and eosin (H&E) or IHC. For IHC, paraffin-embedded pancreas
sections were deparaffinized, rehydrated, and microwave heated for 15 min in 10 mM citrate buffer (pH 6.0) for antigen retrieval. 3%
hydrogen peroxide was applied to block endogenous peroxidase activity. After 2.5 h of blocking with 10% goat serum, mouse anti-
GLUL or control IgG were applied and incubated overnight at 4C. After wash, slides were incubated with biotinylated secondary
antibody and the streptavidin-biotin complex (Vectastain Elite ABC kit, Vector Laboratories) were applied, each for 30 min at
room temperature with an interval washing. After being rinsed with PBS, the slides were immersed for 5 min in the coloring substrate
3,30-diaminobenzidine (DAB, Sigma-Aldrich Co. LLC. St. Louis, MO) 0.4 mg/mL with 0.003% hydrogen peroxide, then rinsed with
distilled water, counterstained with hematoxylin, dehydrated, and coverslipped. For Sirius Red staining, paraffin-embedded
pancreas sections were deparaffinized, rehydrated, and stained with hematoxylin for 8 mins, followed by staining in Picro SiriusCell Reports 29, 1287–1298.e1–e6, October 29, 2019 e3
Red (Direct Red 80, Sigma 365548; Picric acid, Sigma 197378) for 1 h. After washing in two changes of 0.5% acidified water, slides
were dehydrated and coverslipped. H&E and IHC slides were examined using light microscopy (Eclipse Ci, Nikon Instruments) and
photographed using a digital camera (DS-F/3, Nikon Instruments).
Cell growth/proliferation assays
Manual counting
Cells were trypsinized off culture dishes, then counted with a hemocytometer. Cell culture was photographed using a Keyence BX-Z
microscope.
Crystal violet staining
Cells were seeded at equal density in triplicate wells in 12-well plates. The following day, an initial seeding plate was fixed with 4%
PFA. Remaining plates were washed three times with PBS before receiving deficient or supplemented media. Cells were cultured for
72 h, then fixed with 4% PFA. After fixation, cells were stained with 0.1% crystal violet. Stain was eluted with 10% acetic acid and
absorbance measured at 590 nm.
IncuCyte measurement
Cells were seeded at 4x104 cells per well in twelve well plates with variousmedium conditions. Cell proliferation assaywas performed
for three days using IncuCyte Live Cell Analysis System and analyzed using IncuCyte Zoom.
Celigo Cell Imager
Cells were seeded at 1,000 cells per well in 96-well plates with various medium conditions. Automated cell proliferation and death
assays (by propidium iodide (PI) staining) were performed daily.
In vitro proliferation assay on mouse organoids
Organoids were dissociated into single cells with TrypLE Express Enzyme (ThermoFisher). Cells were counted and diluted to
10 cells/ml in a mixture of experimental medium: AdDMEM/F12 medium supplemented with HEPES (1x, Invitrogen), Glutamax
(1x, Invitrogen), penicillin/streptomycin (1x, Invitrogen), B27 (1x, Invitrogen), R-spondin-conditioned medium (10% v/v, Calvin
Kuo), mNoggin (0.1 mg/ml, Peprotech), Gastrin I (10 nM, Sigma), fibroblast growth factor 10 (FGF10, 0.1 mg/ml, Preprotech), Nicotin-
amide (10mM, Sigma), and A83-01 (0.5 mM, Tocris) and Growth factor-reducedMatrigel (BD, 10% final concentration). 150 mL of this
mixture (1500 cells per well) was plated in 96-well white plates (Nunc), whose wells had been previously coated with poly(2-hydrox-
yethyl methacrylate) (Sigma) to prevent cell adhesion to the bottom of the wells. Cell viability wasmeasured every 24 h using the Cell-
Titer-Glo assay (Promega) and SpectraMax I3 microplate reader (Molecular Devices). Five replicate wells per time point were
measured.
Mitochondrial respiration
Oxygen consumption rate (OCR) and ATP production weremeasured using a Seahorse Biosciences extracellular flux analyzer (XF24)
as described previously (Guo et al., 2011). Briefly, cells were seeded at 5x104 cells per well in the XF24 plates. Next day, cells were
preincubated in various medium conditions, and basal OCRs and ATP levels were measured.
Synthesis of 13C-labled dimethyl 2-oxopentanedioate (13C5-dmKG)
p-toluenesulfonic acid monohydrate (38 mg, 0.2 mmol, 0.1 equiv) was added to the solution of 13C5-aKG (300 mg, 1.98 mmol,
Cambridge Isotope Laboratories CLM-2411-PK) in CHCl3 (10 mL) and MeOH (3 mL). The resulting reaction mixture was stirred at
room temperature overnight. The solvent was removed and the residue was purified by flash column chromatography (hexane/
ethylacetate = 2:1) to afford the pure product 308 mg (yield 89%, colorless oil, purity > 95%). 1H NMR (600 MHz, CDCl3) d 3.83
(dd, J = 4.0 Hz, 3H), 3.63 (d, J = 4.0 Hz, 3H), 3.21 (dd, J = 5.2, 4.6 Hz, 1H), 3.00 (dd, J = 10.7, 4.9 Hz, 1H), 2.73 (dd, J = 10.7,
4.6 Hz, 1H), 2.51 (dd, J = 10.9, 4.8 Hz, 1H). All chemicals and reagents were purchased from commercial suppliers and used without
further purification. Proton Nuclear Magnetic Resonance (1H-NMR) spectra were recorded on a Bruker DRX-600 spectrometer.
LC-MS
To assay the total level of metabolite pools, cells were seeded in 100 mm dishes at equal cell number. Cells were washed three times
with PBS before culturing in media with stable isotope tracers. After tracing, media was aspirated, then quickly overlaid with a
40:40:20 mixture of methanol:acetonitrile:water with 0.5% formic acid. The plates were incubated on ice for 5 min, then 50 mL of
15% NH4HCO3 was added to neutralize the acetic acid. Cells were scraped into microfuge tubes, and centrifuged for 10 min at
15,000 x g at 4C. The supernatant was collected for LC-MS.
The LC-MSmethod involved hydrophilic interaction chromatography (HILIC) coupled with electrospray ionization to theQ Exactive
PLUS hybrid quadrupole-orbitrap mass spectrometer (Thermo Scientific). The LC separation was performed on a XBridge BEH
Amide column (150mm3 2.1 mm, 2.5 mmparticle size, Waters, Milford, MA) using a gradient of solvent A (95%/5%H2O/ acetonitrile
with 20 mM ammonium acetate and 20 mM ammonium hydroxide, pH 9.4), and solvent B (20%/80% H2O/acetonitrile with 20 mM
ammonium acetate and 20 mM ammonium hydroxide, pH 9.4). The gradient was 0 min, 100% B; 3 min, 100% B; 3.2 min, 90% B;
6.2 min, 90% B; 6.5 min, 80% B; 10.5 min, 80% B; 10.7 min, 70% B; 13.5 min, 70% B; 13.7 min, 45% B; 16 min, 45% B; 16.5 min,
100% B; 22 min, 100% B. The flow rate was 300 mL/min. Injection volume was 5 mL and column temperature 25C. The automatice4 Cell Reports 29, 1287–1298.e1–e6, October 29, 2019
gain control (AGC) target was 3 3 106. The maximum injection time was 50 ms. Scan range was 75-1,000. The metabolite features
were extracted in MAVEN (Melamud et al., 2010) with the labeled isotope specified and a mass accuracy window of 5 ppm. The
isotope natural abundance and tracer isotopic impurity was corrected using AccuCor (Su et al., 2017).
In vivo and ex vivo stable isotope labeling
For jugular vein catheterization, the procedure was modified from work previously described (Poillet-Perez et al., 2018). In brief,
3-6week oldmicewere anaesthetized using isoflurane carried by 2%oxygen, followed by the placement of a central venous catheter
(polyurethane tubing, 1 F in OD) (SAI Infusion Technologies) into the right jugular vein. A minimal amount of blood was carefully
withdrawn to verify the catheter patency. The proximal end of the catheter was then tunneled subcutaneously, exited between
the shoulder blades and properly secured with a catheter button (Instech Laboratories). Catheterized mice were allowed at least
3 d to fully recover. Afterward, the button and catheter were connected to an infusion pump (NewEra Pump System) through amouse
tether and swivel system (Instech Laboratories). Ammonia isotope tracer (150 mM, 15N-NH4Cl, NLM-467-PK, Cambridge Isotope
Laboratories) was dissolved in sterile saline and infused at a rate of 15 nmol/g/min (0.1 ml/g/min) for 3 h. Infusion rate was determined
and optimized based on serial infusions with different concentration of the tracer (data not shown). Mice were sacrificed and tissues
(serum, pancreas, liver, and kidney analysis) were collected and analyzed by LC-MS. The isotope natural abundance and impurity of
labeled substrate were corrected using a matrix-based algorithm. The construction of the purity matrix and C/N joint correction
matrix is similar to AccuCor39.
For ex vivo stable isotope labeling, mice were sacrificed and necropsied to harvest pancreatic tissue. The pancreas (tumor laden)
was roughly divided into multiple pieces then cultured in glutamine free DMEM supplemented with 10% dialyzed FBS and 1.5 mM
13C5-dmKG for 1 h. After the 1 h incubation, tissues were collected, frozenwithWollenberger clamp, and stored at80C. Tissuewas
processed as described above for in vivo tracing and submitted for LC/MS.
Orthotopic implantation and tumor Imaging
Cells were trypsinized and washed twice in PBS. 6-8 week old mice were anesthetized with a mixture of 100 mg/kg ketamine and
10 mg/kg xylazine. For orthotopic pancreatic tumor growth, the abdomen was shaved and swabbed with a sterile alcohol pad
followed by povidone-iodide scrub. A small vertical incision was made over the left lateral abdominal area, to the left of the spleen.
The head of the pancreas attached to the duodenum was located. Using a sterile insulin syringe, 5 million cells in 100 mL PBS were
injected into the head of the pancreas. The injection site was pressed with a sterile cotton swab to prevent leakage. The abdominal
and skin incisions were closed with 5-0 silk black braided sutures. The mice were given an intraperitoneal injection of 2 mg/kg
Ketorolac immediately after surgery. To monitor tumor growth, the animals were injected intraperitoneally with 100 mg/kg RediJect
D-Luciferin (PerkinElmer) and imaged on the IVIS Lumina III imaging system (Xenogen). Data were analyzed using Living Image v4.3.1
software.
Mouse organoids culture and in vivo transplantation assay
Organoids were cultured as described (Boj et al., 2015) and quickly harvested on ice in AdDMEM/F12 media supplemented
with HEPES (1x, Invitrogen), Glutamax (1x, Invitrogen), and penicillin/streptomycin (1x, Invitrogen). For the orthotopic engraftment
of mouse organoids, 6-8 week old mice were anesthetized using Isoflurane and subcutaneous administration of Ketoprofen
(5 mg/kg). The surgery site was disinfected with Iodine solution and 70% ethanol. An incision was made in the upper left quadrant
of the abdomen. Organoids were dissociated to single cells with TrypLE Express Enzyme (ThermoFisher). 25,000 cells/mouse were
resuspended in 50 mL of growth factor-reduced Matrigel (BD) diluted 1:1 with cold PBS and injected in the tail region of the pancreas
of 6 weeks-old female athymic Nu/Nu mice (Charles Rivers Laboratories). The incision at the peritoneal cavity was sutured with
Coated Vicryl suture (Ethicon) and the skin was closed with wound clips (Reflex7, CellPoint Scientific Inc). Mice were euthanized
43 d after the surgery. When a tumor was found upon necropsy, it was dissected out, photographed, and weighted on a lab scale.
If no tumor was found, the pancreas and spleen were dissected out and examined for fluorescence signal. Tumor weight was
counted as zero if the lesions are too small to be dissected and weighted, although the engraftment might be visible in the GFP
images. Tumors were imaged on a Zeiss SteREO Discovery V8 microscope using Axiovision software.
CRISPR/Cas9 knockout in organoids
pLenti-Cas9-Puro and LRNG-sgGLUL plasmids were sequentially introduced into murine T23 organoids. Briefly, lentiviruses were
produced in HEK293T cells by transfecting plasmids and packaging plasmids (pMD2 and psPAX2) with X-tremeGENE9 transfection
reagent (Roche), concentrated with LentiX concentrator (Clontech), and resuspended in organoid culture media supplemented with
Y-27632 (10 mM, Sigma). Organoids were dissociated to single cells with TrypLE Express Enzyme (ThermoFisher). 100,000 cells
were resuspended with concentrated lentivirus supplemented with polybrene (final concentration; 8 mg/mL), and spinoculated at
600 RCF for 45 min at room temperature. Two d after infection, G418 (1 mg/mL) and puromycin (2 mg/mL) were added for antibiotic
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All mouse experiments were done in compliance with the Institutional Animal Care and Use Committee guidelines at Rutgers
University, Cold Spring Harbor Laboratory, and Stony Brook University. Mice implanted with tumor cells were monitored by IVIS
imaging every week for tumor growth. Death, weight loss ofR 15% body weight, or inability to move were considered as endpoints
when surviving animals would be euthanized.
QUANTIFICATION AND STATISTICAL ANALYSIS
All cell culture and isotope tracing experiments except for Figure S3B were performed at least three times, each with a triplicate. In-
dependent two-sample and one sample t tests were used to make comparisons between two groups and to evaluate whether fold
changes are different from one, respectively. Two tailed Student’s t test was performed for the xenograft tumor growth experiments.
The analyses were mainly carried out using GraphPad Prism or Excel. The survival curves were analyzed by log-rank test. Different
levels of statistical significance are indicated as: n.s.: non-significant, *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.
DATA AND CODE AVAILABILITY
GLUL gene amplification across human cancers was analyzed using cBioPortal (http://www.cbioportal.org). The Human Protein
Atlas (http://www.proteinatlas.org) was used to analyze GLUL IHC staining various tumor tissues. Oncomine (https://www.
oncomine.org) datasets were analyzed for GLUL mRNA expression levels in normal pancreatic tissue and pancreatic cancer. For
Figures 1D–1G, a total of 178 pancreatic adenocarcinoma (PAAD) samples having both RNaseq and clinical data were extracted
from TCGA GDAC Firehose dataset 2016. R software was used to plot the GLUL expression among different clinical phenotypes.
Sub-groups with sample size less than 5 or clinical information uncertain/unknown were excluded.e6 Cell Reports 29, 1287–1298.e1–e6, October 29, 2019
